Johnson & Johnson on Monday announced a $3.1 billion deal to buy privately-held cancer biotech Halda Therapeutics, the latest in a cavalcade of biotech acquisitions as the sector has heated up over the past few months.
Halda’s lead drug, called HLD-0915, is being tested in a Phase 1/2 clinical trial as a treatment for prostate cancer. The drug uses what the company calls a “hold and kill mechanism” to target and kill cancer cells, and is one of a number of medicines the company has under development.
Market Data 
Markets 
